Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement

Sensei Biotherapeutics, Inc.

Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.
Cash and marketable securities $21.2M at Dec 31, 2025, down from $41.3M at Dec 31, 2024.
Completed acquisition of Faeth Therapeutics; adds oral PIKTOR candidate targeting PI3K/AKT/mTOR.
Concurrent $200M private placement supports Phase 2 endometrial and Phase 1b breast cancer trials.
Topline data from Phase 2 endometrial and start of Phase 1b breast cancer expected by year-end 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sensei Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: net income Net loss was $21.1 million, or $(16.72) per basic and diluted share, EPS $(16.72) per basic and diluted share.

Period: the full year ended December 31, 2025
Net income: Net loss was $21.1 million, or $(16.72) per basic and diluted share
EPS: $(16.72) per basic and diluted share
Result: reported results

Exact text from the filing

breast cancer, with additional opportunities in ovarian and lung cancer.” Full Year 2025 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $21.2 million as of December 31, 2025 as compared to $41.3 million as of December 31, 2024. Research and Development (R&D) Expenses: R&D expenses were $11.0 million for the year ended December

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.